Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

M.V. Dieci, P. Conte, G. Bisagni, A.A. Brandes, A. Frassoldati, L. Cavanna, A. Musolino, F. Giotta, A. Rimanti, O. Garrone, E. Bertone, K. Cagossi, S. Sarti, A. Ferro, F. Piacentini, A. Maiorana, E. Orvieto, M. Sanders, F. Miglietta, S. BalduzziR. D'Amico, V. Guarneri

Research output: Contribution to journalArticle

Abstract

Background There is the need to identify new prognostic markers to refine risk stratification for HER2-positive early breast cancer patients. The aim of this study was to evaluate the association of tumor-infiltrating lymphocytes (TILs) with distant disease-free survival (DDFS) in patients with HER2-positive early breast cancer enrolled in the ShortHER adjuvant trial which compared 9 weeks versus 1-year trastuzumab in addition to chemotherapy, and to test the interaction between TILs and treatment arm. Patients and methods Stromal TILs were assessed for 866 cases on centralized hematoxylin and eosin-stained tumor slides. The association of TILs as 10% increments with DDFS was assessed with Cox models. Kaplan-Meier curves were estimated for patients with TILs ≥20% and TILs
Original languageEnglish
Pages (from-to)418-423
Number of pages6
JournalAnnals of Oncology
Volume30
Issue number3
DOIs
Publication statusPublished - Mar 1 2019

Keywords

  • anthracycline
  • eosin
  • hematoxylin
  • taxane derivative
  • trastuzumab
  • adult
  • Article
  • cancer adjuvant therapy
  • cancer prognosis
  • cancer staging
  • clinical evaluation
  • cohort analysis
  • disease free survival
  • early cancer
  • female
  • follow up
  • human
  • human epidermal growth factor receptor 2 positive breast cancer
  • major clinical study
  • middle aged
  • multicenter study (topic)
  • phase 3 clinical trial (topic)
  • postmenopause
  • priority journal
  • staining
  • treatment duration
  • treatment outcome
  • tumor associated leukocyte

Fingerprint Dive into the research topics of 'Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer'. Together they form a unique fingerprint.

  • Cite this